Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT versus SUPPRELIN LA.
LUPRON DEPOT vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to reduced gonadal steroidogenesis (testosterone and estrogen). Initial transient stimulation may occur.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
3.75 mg IM monthly for endometriosis; 3.75 mg IM monthly or 11.25 mg IM every 3 months for central precocious puberty; 7.5 mg IM monthly for prostate cancer.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours after single subcutaneous dose; with depot formulations, the apparent half-life is prolonged due to slow release (e.g., 1-month depot: 30 days).
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Primarily renal (90% as unchanged drug and metabolites); biliary/fecal elimination is minimal.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category C
Category C
GnRH Agonist
GnRH Agonist